Clinical Trial

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-25; most recent amendment 2026-03-21.
Status change: Not Yet Recruiting → Recruiting 2024-10-06
Trial Details
NCT Number NCT06574360
Lead Sponsor China Medical University Hospital
Conditions Schizophrenia
Enrollment 90 participants
Start Date 2024-09-23
Primary Completion 2028-12 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-24